1.22
+0.0092(+0.75%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.21 |
| Day High | 1.24 |
| Day Low | 1.2 |
| 52-Week High | 5.1 |
| 52-Week Low | 1.15 |
| Volume | 73,532 |
| Average Volume | 1.54M |
| Market Cap | 32.07M |
| PE | -0.43 |
| EPS | -2.87 |
| Moving Average 50 Days | 1.9 |
| Moving Average 200 Days | 2.36 |
| Change | 0.01 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $12.22 as of December 18, 2025 at a share price of $1.22. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $84.14 as of December 18, 2025 at a share price of $1.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of all responses were MRD negative) at RP2D, 7.6 mont
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers benefits of FDA working closely wit
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
GlobeNewswire Inc.
Dec 04, 2025 1:45 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo